Arts Journal Denmark
SEE OTHER BRANDS

Hottest arts and entertainment news from Denmark

Arts Journal Denmark: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Arts Journal Denmark.

Press releases published on June 4, 2025

Træhus-Revolution: 3Huse Lancerer Næste Generation Helårshuse

Træhus-Revolution: 3Huse Lancerer Næste Generation Helårshuse

3Huse lancerer bæredygtige helårstræhuse med moderne design, høj energistandard og grøn teknologi – skabt til komfort, holdbarhed og fremtidens boligliv. HELSINGøR, NORDSJæLLAND, DENMARK, June 5, 2025 /⁨EINPresswire.com⁩/ -- Et nyt kapitel i bæredygtig …

‘Sun’s Out, Deals On’: EIN Presswire’s Summer Special Offers Businesses Big Savings on Press Release Packages

‘Sun’s Out, Deals On’: EIN Presswire’s Summer Special Offers Businesses Big Savings on Press Release Packages

Get press releases for as low as $39.96 each with bonus credits and bulk savings WASHINGTON , DC, UNITED STATES, June 4, 2025 /⁨EINPresswire.com⁩/ -- With summer nearly here, warmer days and vacation plans are already in full swing. But the news cycle …

MULTIMEDIA UPDATE -- Game, Set, Match: JOE & THE JUICE Welcomes Novak Djokovic to the Family

MULTIMEDIA UPDATE -- Game, Set, Match: JOE & THE JUICE Welcomes Novak Djokovic to the Family

COPENHAGEN, Denmark, June 04, 2025 (GLOBE NEWSWIRE) -- Today, JOE …

Game, Set, Match: JOE & THE JUICE Welcomes Novak Djokovic to the Family

Game, Set, Match: JOE & THE JUICE Welcomes Novak Djokovic to the Family

COPENHAGEN, Denmark, June 04, 2025 (GLOBE NEWSWIRE) -- Today, JOE …

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action

Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action

     TARPON SPRINGS, Fla., June 4, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual PARP and WNT pathway inhibitor—as …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service